Ranolazine in chronic total occlusion percutaneous coronary intervention
Recommended Citation
Alexandrou M, Mutlu D, Rempakos A, Al Ogaili A, Choi JW, Poommipanit P, Alaswad K, Basir MB, Davies R, Jaffer FA, Dattilo P, Azzalini L, Aygul N, Reddy N, Jefferson BK, Gorgulu S, Khatri JJ, Young LD, Krestyaninov O, Khelimskii D, Frizzell J, Elbarouni B, Rangan BV, Mastrodemos OC, Burke MN, Sandoval Y, and Brilakis ES. Ranolazine in chronic total occlusion percutaneous coronary intervention. J Invasive Cardiol 2024.
Document Type
Article
Publication Date
4-30-2024
Publication Title
The Journal of invasive cardiology
Abstract
Ranolazine is an anti-anginal medication given to patients with chronic angina and persistent symptoms despite medical therapy. We examined 11 491 chronic total occlusion (CTO) percutaneous coronary interventions (PCI) that were performed at 41 US and non-US centers between 2012 and 2023 in the PROGRESS-CTO Registry. Patients on ranolazine at baseline had more comorbidities, more complex lesions, lower procedural and technical success (based on univariable but not multivariable analysis), and higher incidence of major adverse cardiac events (MACE) (on both univariable and multivariable analysis).
PubMed ID
38691399
ePublication
ePub ahead of print
